In Reply We appreciate the commentary by Wormald and Evans on our article.1 In this systematic review and meta-analysis of randomized clinical trials that enrolled patients with atrial fibrillation and venous thromboembolism, a 22% relative reduction in intraocular bleeding with novel anticoagulants compared with warfarin resulted in an absolute risk reduction of 0.8 bleeds per 1000 person-years.